Binary clinical trial risk where Phase 3 BOND-003 failure to meet primary endpoint would eliminate most company value given single-asset focus on cretostim
FDA regulatory risk including potential requirement for additional studies, safety concerns, or rejection of BLA despite positive trial data
Reimbursement risk from Medicare/private payers who may limit coverage for expensive bladder cancer immunotherapies or require step-therapy protocols
Manufacturing scale-up risk for oncolytic virus production requiring specialized facilities and quality control for commercial launch
Ferring's nadofaragene firadenovec already approved for BCG-unresponsive NMIBC creates first-mover advantage and established reimbursement pathways
Potential for improved BCG formulations or combination therapies that reduce addressable patient population of BCG-unresponsive cases
Competition from checkpoint inhibitors (pembrolizumab) gaining traction in bladder cancer with broader oncology infrastructure support
Risk that cretostim clinical data fails to demonstrate meaningful differentiation versus existing approved therapies on efficacy or safety
Cash runway risk with approximately $100M annual burn rate requiring additional financing before potential product approval and revenue generation
Dilution risk to existing shareholders from future equity raises needed to fund commercialization infrastructure and working capital
Concentration risk from single-asset pipeline where cretostim represents substantially all company value with limited backup programs
StructuralCompetitiveBalance Sheet